In summary, these results jointly demonstrate that the inhibition of AHR/MAPK9 mediated by tryptophan-ILA ligand depletion is both sufficient to ameliorate NAFLD-related hepatic steatosis and required for a High BCAA to maximally ameliorate metabolic health. The gene discussed is AHR; the disease is metabolic dysfunction-associated steatotic liver disease.